Cargando…

Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination

Detalles Bibliográficos
Autores principales:	Oskay, T., Isık, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Letters of Biomedical and Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635321/ https://www.ncbi.nlm.nih.gov/pubmed/34853922 http://dx.doi.org/10.1007/s10067-021-05993-0

Ejemplares similares

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Cutaneous reactions after CoronaVac and BioNTech vaccines
por: Öner, Ümran, et al.
Publicado: (2022)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2021)

Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
por: Erol, Çiğdem, et al.
Publicado: (2023)

Reply to Mungmunpuntipantip and Wiwanitkit: CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
por: Sonmezer, Meliha Cagla, et al.
Publicado: (2022)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose
por: Bochnia-Bueno, Lucas, et al.
Publicado: (2023)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
por: Cao, Cheng, et al.
Publicado: (2023)

Reduced CoronaVac vaccine antibody response in patients with chronic kidney disease
por: Akpolat, Tekin
Publicado: (2021)

Evaluation and follow-up of antibody formation after CoronaVac vaccine
por: Çalişir, Büşra, et al.
Publicado: (2022)

Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
por: Phoksawat, Wisitsak, et al.
Publicado: (2022)

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report
por: Onsun, Nahide, et al.
Publicado: (2021)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
por: Tan, Cheng Siang, et al.
Publicado: (2022)

CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)

Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study
por: Medina-Pestana, José, et al.
Publicado: (2021)

CoronaVac: more data for regulators and policy makers
por: Ramasamy, Maheshi N, et al.
Publicado: (2021)

Humoral Immune Response to CoronaVac in Turkish Adults
por: Cosgun, Yasemin, et al.
Publicado: (2023)

Humoral and cellular immune responses to CoronaVac up to one year after vaccination
por: Costa, Priscilla Ramos, et al.
Publicado: (2022)

Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study
por: Medina-Pestana, José, et al.
Publicado: (2021)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Leukocytoclastic vasculitis and COVID-19 vaccination
por: Sookaromdee, P., et al.
Publicado: (2022)

Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19
por: Ozturk, Derya, et al.
Publicado: (2022)

Leukocytoclastic vasculitis after exposure to COVID-19 vaccine()
por: Fritzen, Matheus, et al.
Publicado: (2022)

A Rare Adverse Event after CoronaVac(®)Administration: Neutropenia in a Kidney Transplant Recipient
por: Artan, Ayşe Serra, et al.
Publicado: (2022)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

CoronaVac efficacy data from Turkey – Authors' reply
por: Tanriover, Mine Durusu, et al.
Publicado: (2021)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
por: Bayhan, Gulsum Iclal, et al.
Publicado: (2022)

Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination
por: Costa, Priscilla Ramos, et al.
Publicado: (2022)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
por: Ruenkham, Ayakarn, et al.
Publicado: (2023)

Leukocytoclastic Vasculitis and SARS-COV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g5uaq5sk57a33mh4n143f7le41